Trial Profile
Phase II Open-Label Study of Sunitinib Malate (SUO11248) in Adult Subjects With Metastatic and/or Surgically Unresectable Hepatocellular Cancers (HCC).
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 01 Apr 2012
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 26 Mar 2012 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 01 Jul 2011 Actual end date (Dec 2010) added as reported by ClinicalTrials.gov.
- 01 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.